



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	Attorney Docket No.: STURK0007
)	Confirmation No. 7997
Hanns-Wolf BAENKLER et al)	
)	Group Art Unit: 1743
Serial No.: 10/727,568)	
)	Examiner: Unassigned
Filed: December 5, 2003)	
)	
For: DIAGNOSTIC METHOD BASED ON)	Date: October 12, 2004
LIPID MEASURING PARAMETER)	
MODULATIONS/EFFECTOR)	
QUOTIENT PROFILES)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, this Information Disclosure Statement in connection with the above-identified application is being filed in accordance with 37 C.F.R. §1.97(b):

- ☐ within three months of the filing date of this application (not a C.P.A.);
- ☐ within three months of the date of entry of the National Stage;
- ☒ before the mailing date of a first Office Action on the merits; or
- ☐ before the mailing of a first Office Action on the merits of, after the filing of a Request for Continued Examination (RCE) under §1.114.

A copy of each document listed on the attached Forms PTO/SB/08A and PTO/SB/08B is attached.

Attached is a copy of the International Search Report issued in the corresponding PCT application. Since all of the documents cited herein were cited in said International Search Report or in the specification of the subject application, it is believed that the relevancy of each document cited is clear from the Search Report and specification. Accordingly, no further comment with regard to the disclosures of these documents is believed to be required.


It is respectfully requested that the attached documents be considered and officially cited, and that a copy of Forms PTO/SB/08A and PTO/SB/08B, be initialed by the Examiner and returned to the undersigned to indicate that the documents have been considered.

It is believed that the present Information Disclosure Statement complies with the requirements of 37 C.F.R. §§ 1.97-8, but should the filing of this paper necessitate a fee, the Director is hereby authorized to charge the necessary fee to Deposit Account No.

50-1281.

Respectfully submitted,


GRIFFIN & SZIPL, PC



Joerg-Uwe Szipl
Registration No. 31,799

GRIFFIN & SZIPL, PC
Suite PH-1
2300 Ninth Street, South
Arlington, VA 22204

Telephone: (703) 979-5700
Facsimile: (703) 979-7429
E-mail: g&s@szipl.com
Customer No.: 24203



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/727,568
				Filing Date	December 5, 2003
				First Named Inventor	Hanns-Wolf BAENKLER et al
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	5	Attorney Docket Number	STURK0007


NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	A	D. Schafer et al, "Effect of Prostaglandin E2 on Eicosanoid Release by Human Bronchial Biopsy Specimens From Normal and Inflamed Mucosa", Thorax, BMJ Publishing Group, GB, Vol. 51, No. 9, September 1996, pps. 919-923.		
	B	P. Mohammadian et al, "A reversible inflammation model in man", Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 353, No. 4. Suppl, 1996, p. r150.		
	C	H.W. Baenkler et al, "Eicosanoids From Biopsy of Normal and Polypous Nasal Mucosa", Rhinology, Leiden, NL, Vol. 34, No. 3, 1996, pps. 166-170.		
	D	D.Schafer et al, "Dynamics of Eicosanoids in Peripheral Blood Cells During Bronchial Provocation in Aspirin-Intolerant Asthmatics", European Respiratory Journal, Munksgaard International Publishers, Copenhagen, DK, Vol. 13, No. 3, March 1999, pps. 638-646.		
	E	P.T. Bozza et al, "Mechanisms of Formation and Function of Eosinophil Lipid Bodies: Inducible Intracellular Sites Involved in Arachidonic Acid Metabolism", Memorias Do Instituto Oswaldo Cruz, Rio De Janeiro, Br, Vol. 92, No. Suppl 2, 1997, pps. 135-140.		
	F	C. Pompeia et al, "Fatty Acids and the Immune System", Revista Brasileira De Ciencias Farmaceuticas - Brazilian Journal of Pharmaceutical Sciences, Faculdade de Ciencias Farmaceuticas, Sao Paulo, BR, Vol. 35, No. 2, 1999, pps. 165-194.		
	G	V.G.S. Hirschberg, "Mitteilung uber einen Fall von Nebenwirkung des Aspirin", Dt Med Wochenschr 1902; Vol. 23, pp. 416.		
	H	U.S. von Euler, "Uber die spezifische blutdrucksenkende Substanz des menschlichen Prostata-und Samenblasensekretes", Klin Wschr 1935;14:1182-1185.		
	I	Donald J. Hanahan, "Platelet Activating Factor: A Biologically Active Phosphoglyceride", Ann Rev Biochem, 1986;55: pps. 483-509.		
	J	Mats Hamberg et al, "Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides", Proc. Nat. Acad. Sci. USA 72 (1975) pps. 2994-2998.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known.	
				Application Number	10/727,568
				Filing Date	December 5, 2003
				First Named Inventor	Hanns-Wolf BAENKLER et al
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	5	Attorney Docket Number	STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	K	J.R. Vane, "Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs", Nature New Biology, Vol. 231, June 23, 1971, pps. 232-235.	
	L	Sune Bergstrom, "Prostaglandins: Members of a New Hormonal System", Science, Vol. 157, 1967, pps. 382-391.	
	M	Bengt Samuelsson, "Some Recent Advances in Leukotriene Research", Adv Exp Med Biol 1997; 433, pps. 1-7.	
	N	Bengt Samuelsson et al, "Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects", Science, Vol. 237, 4 September 1987, pps. 1171-1175.	
	O	Michael J. Holtzman, "Arachidonic Acid Metabolism", Am Rev Respir Dis 1991, Vol. 143, pps. 188-203.	
	P	William L. Smith, "The eicosanoids and their biochemical mechanisms of action", Biochem. J., 1989, Vol. 259, pps. 315-324.	
	Q	Armel Fradin et al, "Platelet-Activating Factor and Leukotriene Biosynthesis in Whole Blood - A Model for the Study of Transcellular Arachidonate Metabolism", The Journal of Immunology, Vol. 143, No. 11, December 1, 1989, pps. 3680-3685.	
	R	D. L. Smith et al, "A Suggested Shorthand Nomenclature for the Eicosanoids", LIPIDS, Vol. 22, No. 12, 1987, pps. 983-986.	
	S	E.J. Corey et al, "Recent Studies on the Chemical Synthesis of Eicosanoids", Adv Prostaglandin Thromboxane Res 1980, Vol. 6, pps. 19-25.	
	T	A. L. Willis et al, "Metabolism of Arachidonic Acid: An Overview", The Handbook of Immunopharmacology, Lipid Mediators, Ed.: Cunningham F.M., Academic Press, London, 1994, pps. 1-32.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/727,568
				Filing Date	December 5, 2003
				First Named Inventor	Hanns-Wolf BAENKLER et al
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	3	of	5	Attorney Docket Number	STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	U	T. F. Slater et al, "Introduction to the eicosanoids", Prostaglandins and related substances, eds.: Benedetto C, McDonald-Gibson RG, Nigam S, Slater TF, IRL Press, Oxford, 1987, pps. 1-4.	
	V	David W. Stanley-Samuelson, "Physiological Roles of Prostaglandins and Other Eicosanoids in Invertebrates", Biol. Bull, Vol. 173, August 1987, pps. 92-109.	
	W	M.V. Bell et al, "The Role of Polyunsaturated Fatty Acids in Fish", Comp. Biochem. Physiol. Vol. 83B, No. 4, 1986, pps. 711-719.	
	X	Edward A. Dennis, "Diversity of Group Types, Regulation, and Function of Phospholipase A2", The Journal of Biological Chemistry, Vol. 269, No. 18, May 6, 1994, pps. 13057-13060.	
	Y	Christophe Creminon et al, "Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays", Biochimica et Biophysica Acta, Vol. 1254, 1995, pps. 341-348.	
	Z	Gary P. O'Neill et al, "Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues", Federation of European Biochemical Societies, Vol. 330, No. 2, September 1993, pps. 156-160.	
	AA	I. Kennedy et al, "Studies on the Characterisation of Prostanoid Receptors: A Proposed Classification", Prostaglandins, Vol. 24, No. 5, November 1982, pps. 667-689.	
	BB	David L. DeWitt et al, "Serum Glucocorticoid Regulation of Gene Transcription and Expression of the Prostaglandin H Synthase-1 and Prostaglandin H Synthase-2 Isozymes", Archives of Biochemistry and Biophysics" Vol. 306, No. 1, October 1993, pps. 94-102.	
	CC	P.J. Gardiner et al, "Leukotriene Receptors and Their Selective Antagonists", Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 22, 1994, pps. 49-61.	
	DD	Ju-Lun Hong et al, "Cigarette smoke-induced bronchoconstriction: cholinergic mechanisms, tachykinins, and cyclooxygenase products", J Appl Physiol, Vol. 78, 1995, pps. 2260-2266.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/727,568		
		Filing Date	December 5, 2003		
		First Named Inventor	Hanns-Wolf BAENKLER et al		
		Art Unit	Unknown		
		Examiner Name	Unknown		
Sheet	4	of	5	Attorney Docket Number	STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EE	Robert A. Coleman et al, "Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes", Pharmacol rev., Vol. 46, No. 2, 1994, pps. 205-229.	
	FF	G.W. Taylor et al; "Measurements of Fatty Acids and Their Metabolites", Lipid Mediators, ed. Cunningham F.M., Academic Press, London, 1994, pps. 33-59.	
	GG	Richard J. Kulmacz et al, "Cyclo-oxygenase: measurement, purification and properties", Prostaglandins and related substances, eds. Benedetto C., McDonald-Gibson R.G., Nigam S., Slater T.F., Oxford University Press, Oxford, 1989, pps. 209-227.	
	HH	Tankred Schewe et al, "Lipoxygenases: measurement, characterization and properties", Prostaglandins and related substances, eds. Benedetto C., McDonald-Gibson R.G., Nigam S., Slater T.F., Oxford University Press, Oxford, 1989, pps. 229-242.	
	II	Jaime Vilaseca et al, "Participation of Thromboxane and Other Eicosanoid Synthesis in the Course of Experimental Inflammatory Colitis", Gastroenterology, Vol. 98, No. 2, 1990, pps. 269-277.	
	JJ	A.L. de Weck, "Cellular Allergen Stimulation Test (CAST) - A New Dimension in Allergy Diagnostics", Allergy Clin Immunol News, Vol. 5, 1993, pps. 9-14.	
	KK	H. W. Baenkler et al, "Eicosanoids from biopsy of normal and polypous nasal mucosa", Rhinology, Vol. 34, 1996, pps. 166-170.	
	LL	S.K. Sauer et al, "Stimulated Prostaglandin E2 Release From Rat Skin, In Vitro", Life Science, Vol. 62, No. 22, 1998, pps. 2045-2055.	
	MM	D. Schafer et al, "Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics", European Respiratory Journal, Vol. 13, 1999, pps. 638-646.	
	NN	Jay Y. Westcott, "The Measurement of Leukotrienes in Human Fluids", Clinical Reviews in Allergy and Immunology, Vol. 17, 1999, pps. 153-177.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/727,568
				Filing Date	December 5, 2003
				First Named Inventor	Hanns-Wolf BAENKLER et al
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	5	of	5	Attorney Docket Number	STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	OO	Phillip Greenspan et al, "Nile Red: A Selective Fluorescent Stain for Intracellular Lipid Droplets", The Journal of Cell Biology, Vol. 100, March 1985, pps. 965-973.	
	PP	Ann M. Dvorak et al, "Lipid Bodies: Cytoplasmic Organelles Important to Arachidonate Metabolism in Macrophages and Mast Cells", The Journal of Immunology, Vol. 131, No. 6, December 1983, pps. 2965-2976.	
	QQ	Peter F. Weller et al, "Arachidonic Acid Incorporation by Cytoplasmic Lipid Bodies of Human Eosinophils", Blood, Vol. 65, No. 5, May 1985, pps. 1269-1274.	
	RR	International Search Report, completed 19 September 2002 (4 pages).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.